GLDN
Gliomedin
Also known as: CLOM, COLM, colmedin, CRG-L2, GLDN_HUMAN, UNC-122
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6ZMI3
- Gene
- GLDN
- Ensembl
- ENSG00000186417
- Chromosome
- 15
- Canonical length
- 551 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Vesicles,Plasma membrane
- Secretome location
- Secreted to extracellular matrix
- Quaternary structure
- Homotrimer
OverviewNCBI Gene
This gene encodes a protein that contains olfactomedin-like and collagen-like domains. The encoded protein, which exists in both transmembrane and secreted forms, promotes formation of the nodes of Ranvier in the peripheral nervous system. Mutations in this gene cause a form of lethal congenital contracture syndrome in human patients. Autoantibodies to the encoded protein have been identified in sera form patients with multifocal motor neuropathy. [provided by RefSeq, May 2017]
Canonical amino-acid sequenceUniProt
551 residues, UniProt reviewed canonical sequence.
>Q6ZMI3|GLDN
1 MARGAEGGRG DAGWGLRGAL AAVALLSALN AAGTVFALCQ WRGLSSALRA LEAQRGREQR
61 EDSALRSFLA ELSRAPRGAS APPQDPASSA RNKRSHSGEP APHIRAESHD MLMMMTYSMV
121 PIRVMVDLCN STKGICLTGP SGPPGPPGAG GLPGHNGLDG QPGPQGPKGE KGANGKRGKM
181 GIPGAAGNPG ERGEKGDHGE LGLQGNEGPP GQKGEKGDKG DVSNDVLLAG AKGDQGPPGP
241 PGPPGPPGPP GPPGSRRAKG PRQPSMFNGQ CPGETCAIPN DDTLVGKADE KASEHHSPQA
301 ESMITSIGNP VQVLKVTETF GTWIRESANK SDDRIWVTEH FSGIMVKEFK DQPSLLNGSY
361 TFIHLPYYFH GCGHVVYNNS LYYHKGGSNT LVRFEFGQET SQTLKLENAL YFDRKYLFAN
421 SKTYFNLAVD EKGLWIIYAS SVDGSSILVA QLDERTFSVV QHVNTTYPKS KAGNAFIARG
481 ILYVTDTKDM RVTFAFDLLG GKQINANFDL RTSQSVLAML AYNMRDQHLY SWEDGHLMLY
541 PVQFLSTTLN QLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GLDN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 44 nTPM
Expression across tissuesHPA
Tissue
- spinal cord: 44 nTPM
- midbrain: 33 nTPM
- hippocampal formation: 21 nTPM
- blood vessel: 21 nTPM
- adipose tissue: 17 nTPM
- basal ganglia: 14 nTPM
Single-cell type
- oligodendrocytes: 607 nCPM
- syncytiotrophoblasts: 334 nCPM
- microglia: 221 nCPM
- monocyte progenitors: 92 nCPM
- schwann cells: 91 nCPM
- macrophages: 81 nCPM
Immune cell
- plasmacytoid DC: 0.3 nTPM
- non-classical monocyte: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- white matter: 184 nTPM
- pons: 129 nTPM
- basal ganglia: 118 nTPM
- midbrain: 115 nTPM
- medulla oblongata: 113 nTPM
- thalamus: 100 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GLDN.
Disease | AllUniProt
Conditions GLDN is implicated in, by any mechanism.
- Lethal congenital contracture syndrome 11 (LCCS11) MIM:617194
Disease | GeneticClinVar
27 pathogenic / likely-pathogenic of 188 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Lethal congenital contracture syndrome 11
- Polyhydramnios
- Multiple joint contractures
- Fetal akinesia deformation sequence 1
- GLDN-related disorder
ReferencesPubMed · IEDB
Publications for GLDN from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Nodal proteins are target antigens in Guillain-Barré syndrome.
2012 · J Peripher Nerv Syst · RCR 5 · 152 citations - Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier.
2012 · Am J Pathol · RCR 1.5 · 44 citations - Anti-GLDN antibody-associated CIDP (nodopathy): transient IVIg response and B-cell depletion remission.
2026 · BMC Neurol
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.27
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.13
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GLDN in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GLDN as an antibody target. Whether an autoantibody or antibody against GLDN could matter depends on whether native GLDN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GLDN is annotated at the cell surface, where native GLDN is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Source-annotated serology context
The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.
- Autoantibodies to the encoded protein have been identified in sera form patients with multifocal motor neuropathy.
Loading the interactive Seroatlas protein explorer...